DDIT3 and Hodgkins lymphoma: The Scholz groupmodeled the effect of CHOP-14 therapy supported by ironsupplements and EPO on erythropoiesis and iron metabolism.CHOP-14 is a commonly accepted therapy for treating aggressivenon-Hodgkin lymphomas, including drugs such asdoxorubicin, cyclophosphamide, vincristine, and prednisolone.Currently, the therapy has been extended to R-CHOP,which also includes rituximab (Phan et al., 2010).